155 related articles for article (PubMed ID: 32414613)
1. Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients.
Hutt D; Bielorai B; Baturov B; Z'orbinski I; Ilin N; Adam E; Itzhaki O; Besser MJ; Toren A; Jacoby E
Transfus Apher Sci; 2020 Aug; 59(4):102769. PubMed ID: 32414613
[TBL] [Abstract][Full Text] [Related]
2. Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients.
Jarisch A; Rettinger E; Sörensen J; Klingebiel T; Schäfer R; Seifried E; Bader P; Bonig H
J Clin Apher; 2020 Sep; 35(5):398-405. PubMed ID: 32750197
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
Ceppi F; Rivers J; Annesley C; Pinto N; Park JR; Lindgren C; Mgebroff S; Linn N; Delaney M; Gardner RA
Transfusion; 2018 Jun; 58(6):1414-1420. PubMed ID: 29536556
[TBL] [Abstract][Full Text] [Related]
4. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
Cells; 2020 May; 9(5):. PubMed ID: 32429189
[TBL] [Abstract][Full Text] [Related]
5. [Clinical experience of leukapheresis for CD19 CAR-T cell therapy].
Jo T; Yoshihara S; Arai Y; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Matsui K; Niwa N; Nakagawa Y; Kitawaki T; Kanda J; Takaori-Kondo A; Nagao M
Rinsho Ketsueki; 2021; 62(3):163-169. PubMed ID: 33828008
[TBL] [Abstract][Full Text] [Related]
6. Leukapheresis for CAR-T cell production and therapy.
Pessach I; Nagler A
Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
[TBL] [Abstract][Full Text] [Related]
7. Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel.
Leone G; Baldini V; Bramanti S; Crocchiolo R; Gattillo S; Ermini S; Giudice V; Ferrero I; Moscato T; Milani R; Gozzer M; Piccirillo N; Tassi C; Tassi V; Coluccia P
Blood Transfus; 2023 Nov; 21(6):514-525. PubMed ID: 37146295
[TBL] [Abstract][Full Text] [Related]
8. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
[TBL] [Abstract][Full Text] [Related]
9. Autologous lymphapheresis for the production of chimeric antigen receptor T cells.
Allen ES; Stroncek DF; Ren J; Eder AF; West KA; Fry TJ; Lee DW; Mackall CL; Conry-Cantilena C
Transfusion; 2017 May; 57(5):1133-1141. PubMed ID: 28236305
[TBL] [Abstract][Full Text] [Related]
10. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
Carbonell D; Monsalvo S; Catalá E; Pérez-Corral A; Villegas C; Falero C; Ruano G; Martinez M; Kwon M; Muñoz-Martínez C; Díez-Martín JL; Gayoso J; Anguita J
Blood Transfus; 2024 May; 22(3):239-245. PubMed ID: 38063787
[TBL] [Abstract][Full Text] [Related]
11. Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.
Harrer DC; Heidenreich M; Fante MA; Müller V; Haehnel V; Offner R; Burkhardt R; Herr W; Edinger M; Wolff D; Thomas S; Brosig A
Transfusion; 2022 Aug; 62(8):1602-1611. PubMed ID: 35851959
[TBL] [Abstract][Full Text] [Related]
12. Optimization of lymphapheresis for manufacturing autologous CAR-T cells.
Yamanaka I; Yamauchi T; Henzan T; Sakoda T; Miyamoto K; Mishima H; Ono H; Koga Y; Nakashima Y; Kato K; Miyamoto T; Mizuno S; Ogawa Y; Ohga S; Akashi K; Maeda T; Kunisaki Y
Int J Hematol; 2021 Oct; 114(4):449-458. PubMed ID: 34275066
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cell collection efficiency in non-mobilized adult donors for autologous chimeric antigen receptor T-cell manufacturing.
Piñeyroa JA; Cid J; Vlagea A; Carbassé G; Henao P; Bailo N; Ortiz-Maldonado V; Martínez-Cibrian N; Español M; Delgado J; Urbano-Ispizua Á; Lozano M
Vox Sang; 2023 Mar; 118(3):217-222. PubMed ID: 36516201
[TBL] [Abstract][Full Text] [Related]
14. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
[TBL] [Abstract][Full Text] [Related]
15. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
16. Building blocks for institutional preparation of CTL019 delivery.
McGuirk J; Waller EK; Qayed M; Abhyankar S; Ericson S; Holman P; Keir C; Myers GD
Cytotherapy; 2017 Sep; 19(9):1015-1024. PubMed ID: 28754600
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.
Tuazon SA; Li A; Gooley T; Eunson TW; Maloney DG; Turtle CJ; Linenberger ML; Connelly-Smith LS
Transfusion; 2019 May; 59(5):1773-1780. PubMed ID: 30729531
[TBL] [Abstract][Full Text] [Related]
18. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
[TBL] [Abstract][Full Text] [Related]
19. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of peripheral blood stem cell collection in large-volume leukapheresis for pediatric patients undergoing chemotherapy and adult patients before chemotherapy.
Yamaguchi E; Yamato K; Miyata Y
J Hematother Stem Cell Res; 2000 Aug; 9(4):565-72. PubMed ID: 10982257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]